ALSUntangled 59: Tamoxifen

ALSUntangled No. 22: Propofol.

ISSN 2167-8421 print/ISSN 2167-9223 online © 2013 Informa Healthcare DOI: 10.3109/21678421.2013.826469 neuroinfl ammation (18,19) occur in ALS, although attempts to manipulate these events have not yet shown clear benefi ts in human ALS trials. Propofol has a short half-life; once infusion is stopped, its clinical effects last only minutes (3). For this reason, it is diffi cult to understand ho...

ALSUntangled No. 34: GM604

ALSUntangled update 4: investigating the XCell-Center.

ALSUntangled No. 11: Nu Tech Mediworld.

Now 26 months old, ALSUntangled (www.alsuntangled. org) investigates alternative and off-label treatment options in ALS using social networking tools. Our twitter and NING memberships continue to grow. To date we have published 10 investigations on 11 different alternative and off-label treatment options, collaborating with Quackwatch (www. quackwatch.org), Patients Like Me (www.patients likeme...

ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS.

The mechanism of Aimspro remains unproven; if it is an immunomodulator and/or a modulator of sodium channels, it theoretically could be useful in ALS. A single, detailed but significantly flawed case report documents slowing in decline of certain respiratory functions in a patient claiming to have ALS, who started Aimspro shortly after bipap. Based upon this limited information, ALSUntangled su...